NCT06671613

Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer

Evaluating the Impact of Intermittent Fasting in Combination With Checkpoint Inhibitors in Patients With Non-small Cell Lung Cancer

• Status: Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: VA Office of Research and Development · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn the effects of fasting on cancer cells while you get maintenance treatment.

Detailed description

Cancer cells use an increased supply of glucose to make energy and do not have protection against fasting that normal cells do. Because of this, researchers would like to study how fasting may help immunotherapy target cancer cells. Initial studies suggest that fasting may decrease the side effects of immunotherapy and increase the chances of your cancer responding to the immunotherapy. Patient populations will have non-small cell lung cancer in which pembrolizumab have been recommended to treat the cancer as part of standard care

Conditions

• Stage IV NSCLC
• NSCLC
• Immunotherapy
• Fasting Mimicking Diet

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	FMD	Plant-based diet program
COMBINATION_PRODUCT	Regular Diet Plus FMD	Patients will eat a RD with the first 3 cycles, then receive 3 cycles of FMD as they continue cycles 4-6

Timeline

• Start date: 2025-10-27
• Primary completion: 2029-12-31
• Completion: 2030-12-31
• First posted: 2024-11-04
• Last updated: 2025-11-10

Locations

4 sites across 1 country: United States